BELLUS Health  logo
BELLUS Health BLU

Annual report 2022
added 12-28-2024

report update icon

BELLUS Health Deferred Revenue 2011-2026 | BLU

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.
Features of the metric
  • Sources of future cash inflows
    A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
  • Assessment of operational stability
    Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
  • Risks and obligations
    Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
  • Analysis of liquidity and cash flow
    Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
  • Impact on company valuation
    In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue BELLUS Health

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - - 1.67 M 2.04 M 1.58 M 1.51 M 2.71 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.71 M 1.51 M 1.9 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer Deferred Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
86.5 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
563 K - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
1.3 M - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
15.9 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
124 K - 2.54 % $ 160 B franceFrance
Evogene Ltd. Evogene Ltd.
EVGN
119 K $ 0.75 -4.66 % $ 27.9 M israelIsrael
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
2.64 M $ 22.2 -2.07 % $ 3.68 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.69 M - -1.52 % $ 24.7 M usaUSA
Galapagos NV Galapagos NV
GLPG
443 M $ 27.86 -1.97 % $ 2.69 B belgiumBelgium
Advaxis Advaxis
ADXS
165 K - -9.65 % $ 45.9 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
12.5 M $ 1.49 6.43 % $ 235 M franceFrance
Aeterna Zentaris Aeterna Zentaris
AEZS
2.19 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
283 K - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
300 M $ 101.57 -0.48 % $ 27.2 B germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
2.62 M - -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
517 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
6.3 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
957 K - 1.93 % $ 17.4 M usaUSA
AlloVir AlloVir
ALVR
2.66 M - 4.14 % $ 49.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
405 K $ 2.98 2.41 % $ 4.91 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
85.7 K - -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
158 M - - $ 867 M germanyGermany
Applied Therapeutics Applied Therapeutics
APLT
667 K - - $ 8.42 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
1.09 M $ 4.05 -0.98 % $ 433 M usaUSA
Aravive Aravive
ARAV
4.41 M - -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
20.2 M - 17.91 % $ 11.1 M usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
410 K $ 32.99 -0.39 % $ 286 B franceFrance
Alpine Immune Sciences Alpine Immune Sciences
ALPN
35.6 M - - $ 2.17 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
1.72 M - -4.8 % $ 255 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
20.5 M $ 16.36 -0.4 % $ 7.59 B niderlandNiderland
BeiGene, Ltd. BeiGene, Ltd.
BGNE
187 M - 0.49 % $ 251 B cayman-islandsCayman-islands